Candel accelerates unveiling of second enLIGHTEN candidate to AACR April 2024

Candel Therapeutics, Inc.

Second enLIGHTEN platform candidate to be presented at AACR April 9, 2024; originally planned for Q3 2024.
First-in-class multimodal immunotherapy designed to induce tertiary lymphoid structures for solid tumors.
Abstract LB263; poster session on Tuesday April 9, 9:00 AM - 12:30 PM PT in San Diego.
Candidate follows Alpha 201-macro-1; data from preclinical models shown at SITC 2023 and Oncolytic Virus Conference 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.